New Product Newswire

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

The therapy is now the first and only oral on demand treatment option for the condition.

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

Bullous pemphigoid is a rare skin condition that causes large blisters filled with fluids that typically occur near skin creases, such as the upper thighs and armpits.

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.